TARPON SPRINGS, Fla., June 2, 2025-- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback